Key result
The SPARCL study enrolled 4,732 patients with prior stroke or TIA and no known CHD to evaluate the effect of atorvastatin 80 mg/day on secondary stroke prevention.
Why the study?
Does atorvastatin 80 mg/day prevent secondary stroke in patients with prior stroke or TIA and no known CHD?
RCT (n=4,732)
Double-blind
Randomized
Yes
Does atorvastatin 80 mg/day prevent secondary stroke in patients with prior stroke or TIA and no known CHD?
SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention for patients without known CHD.
No takes yet. Share an insight, caveat, or question.
Supports high-intensity statin use after stroke/TIA without CHD; extends secondary prevention evidence beyond coronary disease.
Amarenco et al. (2003) conducted an RCT in Stroke or transient ischemic attack with no known coronary heart disease (n=4,732). Atorvastatin vs. Placebo was evaluated on Secondary stroke prevention. The SPARCL study enrolled 4,732 patients with prior stroke or TIA and no known CHD to evaluate the effect of atorvastatin 80 mg/day on secondary stroke prevention.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: